We are a biopharmaceutical company focused on the development and commercialization of RP-323, a targeted gene repair, immunotherapy, and stem cell activator for treating neurological diseases, blood disorders, and such inflammatory disorders as ARDS (Adult Respiratory Distress Syndrome).
We are happy to announce that you can now be part of this exciting technology and help make a difference by investing in PhorMed through Equity Crowdfunding.
Coming Soon
RP-323 treats diseases upstream where issues start. It has the ability to add a needed phosphate to a pathway, turning the switch on/off inside the DNA, allowing proper DNA transcription and protein expression.
After multiple clinical studies RP-323 has been found to be safe and the company is now prepared to enter into the next phase of clinical trials advancing its pipeline in collaboration with two clinical sites in Atlanta Georgia.
